What We're Reading: Page 170
Industry reads hand-picked by our editors
Nov 10, 2020
-
Reuters
How Pfizer vaccine could be cold comfort for some Asian nations
-
BioCentury
Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes
-
CNN
Brazil suspends trials of China's Sinovac coronavirus vaccine, citing 'serious adverse event'
-
The Wall Street Journal
Biogen Stock Might Not Recover From Alzheimer's Treatment Setback
Nov 09, 2020
Nov 06, 2020
-
Reuters
Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal
-
The New York Times
Opioid Epidemic Settlement Offer, Worth $26 Billion, Gains Support
-
Philadelphia Business Journal
Endo cutting 560 jobs over the next three years
-
Bloomberg
All-or-Nothing Bet on Bristol Drugs Goes Sour as FDA Reviews Lag
Nov 05, 2020
-
The Wall Street Journal
After Rocky Start, FDA’s Hahn Wins Over Skeptics
-
Reuters
WHO-led COVID drug scheme doubles down on antibodies, steroids and shuns remdesivir
-
BioCentury
HHS proposes regulation sunset rule that could create uncertainty for industry, paralyze FDA
-
Bloomberg
China Alzheimer Drug Seeks Global Legitimacy With U.S. Trial
Nov 04, 2020
Nov 03, 2020
-
Reuters
FDA bars critic from review panel of Biogen's controversial Alzheimer's drug
-
STAT
Is Philadelphia’s biotech cluster faltering? Experts say no, even as funding dwindles
-
POLITICO
Health agencies resist Trump civil service executive order
-
FiercePharma
Orchard Therapeutics' gene therapy Strimvelis linked to a leukemia case
Previous
